Mehabe score: 2 G Factor: 4 Piotski Score: 8 The stock has a rating . The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 4 and Piotski score of 8.
Description
Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)Site:AUROPHARMAMain Symbol:AUROPHARMA
Stock trades at 672.0, below its 50dma 782.53 and below its 200dma 854.49. The stock remains bearish on technicals
The 52 week high is at 1063.90 and the 52week low is at 660.10
Price Chart
P/E Chart
Sales and Margin
Strengths
– has delivered good profit growth of 21.38% CAGR over last 5 years
Weakness
– might be capitalizing the interest cost
-Earnings include an other income of Rs.3189.73 Cr.
Competition
– The industry trades at a mean P/E of 26.5x. Piramal Enterp. trades at the industry’s max P/E of 49.58x. AUROPHARMA trades at a P/E of 7.4x
– Industry’s mean G-Factor is 2.2 while the mean Piotski score is 9.0. AUROPHARMA has a G-Factor of 4 and Piotski scoreof 8.
– Average 1 month return for industry is -4.2%. The max 1- month return was given by Piramal Enterp.: a return of 1.07 %
Quarterly Results
Sales for period ended Sep 2021 is Rs 5942.0 cr compared to Rs 6483.0 cr for period ended Sep 2020, a fall of 8.3%
Operating Profits reported at Rs 1176.0 cr for period ended Sep 2021 vis-vis 1412.0 for period ended Sep 2020 .
Operating Margins contracted -198.9 bps for period ended Sep 2021 vis-vis Sep 2020 .
The EPS for Sep 2021 was Rs 11.9 compared to Rs 13.14 for previous quarter ended Jun 2021 and Rs 13.79 for Sep 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 24010.0 cr for period ended TTM vis-vis sales of Rs 24775.0 cr for the period ended Mar 2021, a fall of 3.2%. The 3 year sales cagr stood at 7.1%.
Net Profit reported at Rs 5215.0 cr for period ended TTM vis-vis sales of Rs 5335.0 cr for the period ended Mar 2021, falling 2.3%.
Company recorded a healthy Net Profit CAGR of 30.2% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
CashFlow from operating activities was positive.
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has improved its Return on Equity (RoE) metric. The RoE on Last Year basis was 28.0% compared to 22.0% over the last 3 Years. – The stock has given a return of -14% on a 1 Year basis vis-vis a return of -6% over the last 3 Years. – The compounded sales growth on a TTM bassis is 4% vis-vis a compounded sales growth of 15% over the last 3 Years. – The compounded profit growth on a TTM basis is 79% vis-vis a compounded profit growth of 30% over the last 3 Years.
Ratios
Shareholding Pattern
– FII shareholding has remained largely constant. The Sep 2021 fii holding stood at 21.71% vis-vis 23.7% for Jun 2021 – Public shareholding has remained largely constant. The Sep 2021 public holding stood at 10.93% vis-vis 9.8% for Jun 2021
Conclusion
– has delivered good profit growth of 21.38% CAGR over last 5 years – might be capitalizing the interest cost
-Earnings include an other income of Rs.3189.73 Cr.
